The estimated Net Worth of John Micek is at least $1.48 Tausend dollars as of 17 May 2023. Mr. Micek owns over 1,145 units of Jaguar Health Inc stock worth over $1,476 and over the last 8 years he sold JAGX stock worth over $0. In addition, he makes $0 as Independent Director at Jaguar Health Inc.
John has made over 2 trades of the Jaguar Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 1,145 units of JAGX stock worth $1,294 on 17 May 2023.
The largest trade he's ever made was exercising 12,133 units of Jaguar Health Inc stock on 18 May 2022 worth over $13,710. On average, John trades about 1,328 units every 36 days since 2016. As of 17 May 2023 he still owns at least 1,306 units of Jaguar Health Inc stock.
You can see the complete history of Mr. Micek stock trades at the bottom of the page.
John J. Micek III serves as Independent Director of the Company. Mr. Micek was managing director of Silicon Prairie Partners, LP, a Palo Alto, California based family-owned venture fund. Since 2010, Mr. Micek has been managing partner of Verdant Ventures, a merchant bank dedicated to sourcing and funding university and corporate laboratory spinouts in areas including pharmaceuticals and cleantech. Mr. Micek serves on the board of directors of Armanino Foods of Distinction, Innovare Corporation and JAL/Universal Assurors. He is also a board member and the Chief Executive Officer and Chief Financial Officer of Enova Systems and from March 2014 to August 2015 he served as interim Chief Financial Officer for Smith Electric Vehicles, Inc. Mr. Micek is a cum laude graduate of Santa Clara University and the University of San Francisco School of Law, and is a practicing California attorney specializing in financial services.
John Micek is 67, he's been the Independent Director of Jaguar Health Inc since 2016. There are 1 older and 12 younger executives at Jaguar Health Inc. The oldest executive at Jaguar Health Inc is James Bochnowski, 76, who is the Independent Chairman of the Board.
John's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.
Over the last 9 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski und Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Jaguar Health Inc executives and other stock owners filed with the SEC include: